Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1RA and Metformin in Overweight/Obese Type 2 Diabetes
NCT05779644Unknown
- Sponsor
- Renji Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of liraglutide and semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Renji Hospital. Primary endpoint: Blood glucose at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05779644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779644.